The MiniMab™ SdAbs are expertly engineered for optimal conjugate performance with a selection of best-in-class CF® Dyes for stochastic optical reconstruction microscopy (STORM). The antibodies are also available conjugated to Biotium’s photostable near-infrared CF®740 dye. Unlike conventional antibodies, MiniMab™ SdABs offer:
Deeper tissue penetration for better target accessibility Higher solubility and stability for robust performance Faster staining and superior signal clarity Smaller conjugates for reduced localization error in super-resolution imaging Conjugated to Biotium’s best-in-class CF® Dyes for STORM
Also available with Biotium’s new photostable CF®740 near-IR dye
These features make MiniMab™ reagents a powerful solution for researchers performing immunofluorescence microscopy on both conventional and super-resolution imaging platforms.
PFA-fixed rat brain cryosection stained with MiniMab™ GFAP SdAb (VHH) CF®568 conjugate (orange) and NucSpot® 680/700 Nuclear Stain (magenta). Scale bar: 20 um.
MiniMab™ SdAbs are available conjugated to CF® Dyes for unmatched resolution and signal intensity in synaptic imaging.
GFAP (SdAb2409.GFAP): Targets glial fibrillary acidic protein (GFAP)—a hallmark astrocyte marker in neural tissue. This SdAb enables robust visualization of GFAP isoforms, especially the alpha variant, and is optimized for clarity in astrocytic filament networks. Its high specificity makes it ideal for studying glial cell development, tumor biology, and various CNS disorders. This VHH reacts with human, mouse, and rat GFAP.
VGLUT1 (SdAb2412.VGLUT1): Targets the vesicular glutamate transporter 1, enabling precise visualization of glutamatergic synapses. This SdAb recognizes the cytoplasmic region of rat, mouse, and is expected to react with human VGLUT1 due to sequence homology.
SYT1 (SdAb2501.SYT1): Binds specifically to Synaptotagmin 1, a calcium-sensing protein essential for synaptic vesicle fusion and neurotransmitter release. The SdAb targets the cytoplasmic domain of SYT1 in rats and mice and is expected to cross-react with human SYT1 due to sequence homology.
Biotium is continuing to grow the MiniMab™ SdAb product line to empower researchers with high-performance probes targeting critical cellular structures for neuroscience and other research areas. More MiniMab™ conjugates are currently in development, aimed at offering an expanded toolkit for next-generation imaging.
About Biotium
Biotium is a leading developer and manufacturer of fluorescent reagents and life science tools, serving researchers worldwide with innovative solutions for cell biology, molecular biology, and advanced imaging.
Nanobody® is a registered trademark of Ablynx, a Sanofi company.